Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022

SELL
$30.74 - $49.16 $3.28 Million - $5.24 Million
-106,632 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $31,651 - $70,398
1,008 Added 0.95%
106,632 $3.52 Million
Q2 2021

Aug 11, 2021

SELL
$40.9 - $64.9 $1.28 Million - $2.04 Million
-31,395 Reduced 22.91%
105,624 $6.68 Million
Q1 2021

May 07, 2021

BUY
$40.8 - $57.39 $14,891 - $20,947
365 Added 0.27%
137,019 $5.88 Million
Q4 2020

Feb 03, 2021

BUY
$30.79 - $57.2 $1.24 Million - $2.3 Million
40,239 Added 41.74%
136,654 $7.82 Million
Q3 2020

Nov 04, 2020

SELL
$25.89 - $33.65 $170,822 - $222,022
-6,598 Reduced 6.41%
96,415 $2.91 Million
Q2 2020

Aug 05, 2020

SELL
$24.8 - $38.49 $756,524 - $1.17 Million
-30,505 Reduced 22.85%
103,013 $3.36 Million
Q1 2020

May 06, 2020

BUY
$17.91 - $44.33 $86,362 - $213,759
4,822 Added 3.75%
133,518 $3.58 Million
Q4 2019

Feb 07, 2020

BUY
$22.1 - $30.8 $36,244 - $50,512
1,640 Added 1.29%
128,696 $3.94 Million
Q3 2019

Nov 04, 2019

SELL
$24.09 - $32.18 $127,556 - $170,393
-5,295 Reduced 4.0%
127,056 $3.06 Million
Q2 2019

Aug 07, 2019

SELL
$18.0 - $25.34 $62,946 - $88,613
-3,497 Reduced 2.57%
132,351 $3.35 Million
Q1 2019

May 01, 2019

BUY
$12.81 - $19.82 $75,258 - $116,442
5,875 Added 4.52%
135,848 $2.65 Million
Q4 2018

Feb 04, 2019

BUY
$11.47 - $18.71 $350,523 - $571,777
30,560 Added 30.74%
129,973 $1.71 Million
Q3 2018

Oct 25, 2018

BUY
$16.57 - $21.03 $302,087 - $383,397
18,231 Added 22.46%
99,413 $1.77 Million
Q2 2018

Aug 02, 2018

BUY
$19.63 - $30.0 $1.59 Million - $2.44 Million
81,182 New
81,182 $1.79 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.79B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.